1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

 
• By Derrick Gingery

US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.

Money Wave
Estimates of future BsUFA revenue indicate substantial increases compared to FY 2019 collections. • Source: Shutterstock

Biosimilar user fee collections missed estimates significantly once again in fiscal year 2019, which forced the US Food and Drug Administration to reduce spending to account for the shortfall.

BsUFA collections were nearly $4.2m less than estimates after fee-paying applications were 22% less than expected, the agency said in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Aurobindo, MSN Fail To Beat US Nuplazid Patent Expiring In August 2038

 
• By Dean Rudge

Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis appears safe from generic competition until well into the next decade, following a favorable infringement and validity decision by a US district court.